The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 10, 2021
Filed:
Dec. 11, 2019
Applicant:
Proteostasis Therapeutics, Inc., Boston, MA (US);
Inventors:
Benito Munoz, Newtonville, MA (US);
Cecilia M. Bastos, South Grafton, MA (US);
John Miller, Worcester, MA (US);
Assignee:
Proteostasis Therapeutics, Inc., Boston, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/42 (2006.01); A61P 11/12 (2006.01); A61K 31/341 (2006.01); A61K 31/422 (2006.01); A61K 31/433 (2006.01); A61K 31/454 (2006.01); A61K 31/47 (2006.01); A61K 31/5377 (2006.01); C07D 261/14 (2006.01); C07D 413/14 (2006.01); C07D 407/12 (2006.01); C07D 417/12 (2006.01); C07D 409/14 (2006.01); C07D 405/12 (2006.01); C07D 413/12 (2006.01); C07D 307/54 (2006.01); A61K 31/4178 (2006.01); A61K 31/4245 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/42 (2013.01); A61K 31/341 (2013.01); A61K 31/4178 (2013.01); A61K 31/422 (2013.01); A61K 31/4245 (2013.01); A61K 31/433 (2013.01); A61K 31/454 (2013.01); A61K 31/47 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); A61P 11/12 (2018.01); C07D 261/14 (2013.01); C07D 307/54 (2013.01); C07D 405/12 (2013.01); C07D 407/12 (2013.01); C07D 409/14 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 417/12 (2013.01);
Abstract
The present disclosure features compounds such as those having the Formulae (I) and (II), which can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells. The present disclosure also features methods of treating a condition associated with decreased CFTR activity or a condition associated with a dysfunction of proteostasis comprising administering to a subject an effective amount of a disclosed compound, such as a compound of Formula (I) or (II).